

The Beljanski Foundation Funds Groundbreaking Clinical Trial for Long COVID Treatment Amid Urgent Need

LOS ANGELES, CA, UNITED STATES, April 12, 2023 /EINPresswire.com/ -- The [Beljanski Foundation](#) is sponsoring a new clinical trial for patients with Long COVID because of the urgent need for a new and successful treatment.

Anecdotal reports from patients experiencing lingering symptoms from infection with SARS-CoV-2 started to emerge shortly after the beginning of the pandemic, and the term "Long COVID" was coined to name this

condition and alert the medical and scientific communities. Upwards of 65 million people worldwide are now suffering from this condition.



<https://www.covid.gov/longcovid/definitions>

“

For Long COVID patients with thrombocytopenia, the clinical trial determines whether administration of the RNA fragments relieves their symptoms (fatigue, depression) by boosting their platelet counts”

Dr. John Hall, Director of Research at the Beljanski Foundation

The goal of the trial is to test whether the administration of a special preparation of small RNA fragments, originally developed by Dr. Mirko Beljanski, will help Long COVID patients by stimulating stem cells in the bone marrow to produce new immune cells. An earlier clinical trial, conducted with this special preparation of RNA fragments at Cancer Treatment Centers of America, confirmed its safety and efficacy for treating thrombocytopenia (low platelets) caused by chemotherapy. Thrombocytopenia has been seen in a significant number of Long COVID patients, and low platelets are associated with fatigue - a major symptom of Long COVID. The trial will also reveal the

potential of the RNA fragments to re-balance immunity in these patients.

<https://www.cancercenter.com/clinical-trials-program>

The critical role of RNA primers was first discovered by Okazaki, who showed that short segments of RNA are essential for initiating the synthesis of one of the new strands of DNA. Dr. Beljanski, a biochemist at the Pasteur Institute in Paris, prepared short RNA fragments that specifically prime DNA synthesis in bone marrow stem cells, which triggers the production of our white blood cells and platelets. The RNA fragments have been available as dietary ingredients in the US since the 90s, and a commercial preparation made available by Maison Beljanski will be used for the new clinical trial. The findings are expected to provide valuable insight into whether improving bone marrow function and patient immunity is a pathway for successful Long COVID treatment.

"For Long COVID patients with thrombocytopenia, the clinical trial will determine whether administration of the RNA fragments relieves their symptoms (fatigue, depression) by boosting their platelet counts," says Dr. John Hall, Director of Research at the Beljanski Foundation.

The Beljanski Foundation, Inc, a 501(c)(3) dedicated to researching natural solutions to cancer and other chronic diseases, has received the 2023 Gold Seal of Transparency from GuideStar. Over the last few years, public interest in more research on natural compounds has allowed the Beljanski Foundation to fund several research programs, that were conducted at various academic institutions. Each of its research programs has led to peer-reviewed publications the Foundation shares with the public, on its website, <https://www.beljanski.org>.

To learn more about the Long COVID clinical trial, click here: <https://ecronicon.org/ecnu/clinical-trial-to-test-safety-and-efficacy-of-rna-based-immune-support-in-long-covid-patients>

Eager to learn more about the Beljanski Foundation, click here: <https://www.beljanski.org/>

Aurora DeRose
Boundless Media Inc.
+1 951-870-0099
[email us here](mailto:info@boundlessmedia.com)

ECRONICON
OPEN ACCESS

EC NUTRITION
Mini Review

Clinical Trial to Test Safety and Efficacy of RNA-Based Immune Support in Long COVID Patients

Sylvie Beljanski and John Hall*

The Beljanski Foundation, New York City, New York, USA

*Corresponding Author: John Hall, The Beljanski Foundation, New York City, New York, USA.

Received: March 16, 2023; Published: March 23, 2023

Abstract

The Beljanski Foundation is sponsoring a new clinical trial for patients with Long COVID because of the urgent need for a new and successful treatment. The goal is to test whether administration of a special preparation of small RNA fragments resolves symptoms in Long COVID patients. Originally developed by M. Beljanski, the fragments work by stimulating stem cells in bone marrow to produce our immune cells. Previous research conducted on this special preparation of small RNA fragments at Cancer Treatment Centers of America confirmed their safety and effectiveness for treating thrombocytopenia (low platelets) caused by chemotherapy. Thrombocytopenia, as well as immune dysregulation, have been seen in a significant number of Long COVID patients and low platelets are associated with fatigue, a major symptom of Long COVID. The trial will also reveal the potential of the RNA fragments to re-balance immunity in these patients.

Keywords: Long Covid; COVID-19; SARS-CoV-2; Platelets; Thrombocytopenia; Clinical Trial

Introduction

Anecdotal reports from patients experiencing lingering symptoms from an infection with SARS-CoV-2 started to emerge shortly after the beginning of the pandemic and the term "Long COVID" was coined to name this condition and alert the scientific community.

According to the Centers for Disease Control and Prevention [1], 1 in 5 people infected with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) eventually experience long-term effects from their infection. Other studies indicate that the number is higher [2]. People call post-COVID conditions by many names, including Long COVID, long-haul COVID, post-acute COVID-19, post-acute sequelae of SARS-CoV-2 infection (PASC), long-term effects of COVID, and chronic COVID.

Whatever the name, according to the World Health Organization there have been over 750 million people around the world infected since the inception of the pandemic [3]. Nature Reviews estimates that upwards of 65 million people are currently suffering from Long COVID worldwide [4], and the real numbers could be higher, because – according to the Centers for Disease Control and Prevention – people who are vaccinated are less likely to report post-COVID conditions, compared to people who are unvaccinated [5].

Citation: Sylvie Beljanski and John Hall, "Clinical Trial to Test Safety and Efficacy of RNA-Based Immune Support in Long COVID Patients", EC Nutrition 18.3 (2023): 51-56.

Long COVID Clinical Trial

This press release can be viewed online at: <https://www.einpresswire.com/article/626369235>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.